Desensitization of human CRF2(a) receptor signaling governed by agonist potency and βarrestin2 recruitment

Regulatory Peptides

Volumn 186, Issue , 2013, Pages 62-76

  Hauger, Richard L ^a,b   Olivares Reyes, J Alberto ^c   Braun, Sandra ^b   Hernandez Aranda, Judith ^c   Hudson, Christine C ^d   Gutknecht, Eric ^e,f   Dautzenberg, Frank M ^e,h   Oakley, Robert H ^d,g  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c DEPARTAMENTO DE FÍSICA   (Mexico)

^d Xsira Pharmaceuticals   (United States)

^e JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^f VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^g NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^h Nycomed GmbH   (Germany)

Author keywords

arrestin2; Corticotropin releasing factor receptor (CRF); Urocortin 1 (UCN1); Urocortin 2 (UCN2); Urocortin 3 (UCN3)

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; BETA ARRESTIN 2; CASEIN KINASE; CORTAGINE; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2A; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; SAUVAGINE; STRESSIN1 A; UNCLASSIFIED DRUG; UROCORTIN I; UROCORTIN II; UROCORTIN III; AMPHIBIAN PROTEIN; BETA ARRESTIN; CASEIN KINASE I; CASEIN KINASE II; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; FORSKOLIN; G PROTEIN COUPLED RECEPTOR; PEPTIDE HORMONE; PROTEIN KINASE C; RETINA S ANTIGEN; UCN1 PROTEIN, HUMAN; UCN2 PROTEIN, HUMAN; UCN3 PROTEIN, HUMAN; UROCORTIN;

AGONIST; ANIMAL CELL; ARTICLE; BETA ARRESTIN 2 GENE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISSOCIATION; EMBRYO; GENE DELETION; HUMAN; HUMAN CELL; INTERNALIZATION; LIGAND BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RECEPTOR BINDING; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; STRESS; ΒARRESTIN2; CK1; CK2; CORTICOTROPIN RELEASING FACTOR RECEPTOR (CRF); CRF RECEPTOR TYPE 2(A); CRF(1) RECEPTOR; CRF(2(A)) RECEPTOR; DRUG POTENTIATION; DYNAMIN DOMINANT NEGATIVE MUTANT; G PROTEIN-COUPLED RECEPTOR; GPCR KINASE; GRK; HEK293 CELL LINE; K44A; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; PKA; PKC; PROTEIN PROCESSING; PROTEIN TRANSPORT; SCP; SECOND MESSENGER; SRP; STRESSCOPIN-RELATED PEPTIDE; TUMOR CELL LINE; UROCORTIN 1 (UCN1); UROCORTIN 2 (UCN2); UROCORTIN 3 (UCN3);

ΒARRESTIN2; CASEIN KINASE 1; CASEIN KINASE 2; CK1; CK2; CORTICOTROPIN RELEASING FACTOR RECEPTOR (CRF); CRF RECEPTOR TYPE 1; CRF RECEPTOR TYPE 2(A); CRF(1) RECEPTOR; CRF(2(A)) RECEPTOR; DYNAMIN DOMINANT NEGATIVE MUTANT; G PROTEIN-COUPLED RECEPTOR; GPCR; GPCR KINASE; GRK; K44A; PKA; PKC; PROTEIN KINASE A; PROTEIN KINASE C; SCP; SRP; STRESSCOPIN; STRESSCOPIN-RELATED PEPTIDE; UROCORTIN 1 (UCN1); UROCORTIN 2 (UCN2); UROCORTIN 3 (UCN3);

AMPHIBIAN PROTEINS; ARRESTINS; CELL LINE, TUMOR; COLFORSIN; CORTICOTROPIN-RELEASING HORMONE; CYCLIC AMP; HEK293 CELLS; HUMANS; PEPTIDE HORMONES; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN TRANSPORT; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; SECOND MESSENGER SYSTEMS; UROCORTINS;

EID: 84883628960     PISSN: 01670115     EISSN: 18731686     Source Type: Journal    
DOI: 10.1016/j.regpep.2013.06.009     Document Type: Article

References (52)

1. Hauger R.L., Risbrough V., Brauns O., Dautzenberg F.M. Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets. CNS Neurol Disord Drug Targets 2006, 5:453-479.
2. Perrin M.H., Vale W. Chapter 25: corticotropin-releasing factor receptors. Understanding G protein-coupled receptors and their role in the CNS 2002, 505-526. Oxford University Press, New York. M.N. Pangalos, C.H. Davies (Eds.).
3. Grammatopoulos D.K. Insights into mechanisms of corticotropin-releasing hormone receptor signal transduction. Br J Pharmacol 2012, 166:85-97.
4. Dautzenberg F.M., Hauger R.L. The CRF peptide family and their receptors: yet more partners discovered. Trends Pharmacol Sci 2002, 23:71-77.
5. Grigoriadis D.E. The corticotropin-releasing factor receptor: a novel target for the treatment of depression and anxiety-related disorders. Expert Opin Ther Targets 2005, 9:651-684.
6. Hauger R.L., Risbrough V., Oakley R.H., Olivares-Reyes J.A., Dautzenberg F.M. Role of CRF receptor signaling in stress vulnerability, anxiety, and depression. Ann N Y Acad Sci 2009, 1179:120-143.
7. Bale T.L., Vale W.W. CRF and CRF receptors: role in stress responsivity and other behaviors. Annu Rev Pharmacol Toxicol 2004, 44:525-557.
8. Keck M.E., Ohl F., Holsboer F., Muller M.B. Listening to mutant mice: a spotlight on the role of CRF/CRF receptor systems in affective disorders. Neurosci Biobehav Rev 2005, 29:867-889.
9. Waselus M., Valentino R.J., Van Bockstaele E. Collaterized dorsal raphe nucleus projections: a mechanism for the integration of diverse functions during stress. J Chem Neuroanat 2011, 41:266-280.
10. Lebow M., Neufeld-Cohen A., Kuperman Y., Tsoory M., Gil S., Chen A. Susceptibility to PTSD-like behavior is mediated by corticotropin-releasing factor receptor type 2 levels in the bed nucleus of the stria terminalis. J Neurosci 2012, 32:6906-6916.
11. Risbrough V.B., Hauger R.L., Roberts A.L., Vale W.W., Geyer M.A. Corticotropin releasing factor receptors CRF1 and CRF2 exert both additive and opposing influences on defensive startle behavior. J Neurosci 2004, 24:6545-6552.
12. Risbrough V.B., Geyer M.A., Hauger R.L., Coste S., Stenzel-Poore M., Wurst W., Holsboer F. CRF1 and CRF2 receptors are required for potentiated startle to contextual but not discrete cues. Neuropsychopharmacology 2009, 34:1494-1503.
13. Kohout T.A., Lefkowitz R.J. Regulation of G protein-coupled receptor kinases and arrestins during receptor desensitization. Mol Pharmacol 2003, 63:9-18.
14. Shenoy S.K., Lefkowitz R.J. β-arrestin-mediated receptor trafficking and signal transduction. Trends Pharmacol Sci 2011, 32:521-533.
15. Oakley R.H., Laporte S.A., Holt J.A., Caron M.G., Barak L.S. Differential affinities of visual arrestin, β-arrestin1, and β-arrestin2 with G protein-coupled receptors delineate two major classes of receptors. J Biol Chem 2000, 275:17201-17210.
16. Markovic D., Punn A., Lehnert H., Grammatopoulos D.K. Intracellular mechanisms regulating corticotropin-releasing hormone receptor-2b endocytosis and interaction with extracellularly regulated kinase1/2 and p38 mitogen-activated protein kinase signaling cascades. Mol Endocrinol 2008, 22:689-706.
17. 2(a) receptors endogenously expressed in human retinoblastoma Y79 cells: passage-dependent regulation of functional receptors. J Neurochem 2008, 104:926-936.
18. q coupling in human embryonic kidney 293 but not SK-N-MC neuroblastoma cells. Biochem Pharmacol 2004, 68:1833-1844.
19. Palchaudhuri M.R., Hauger R.L., Wille S., Fuchs E., Dautzenberg F.M. Isolation and pharmacological characterization of two functional splice variants of corticotropin releasing factor type 2 receptor from Tupaia belangeri. J Neuroendocrinol 1999, 11:419-428.
20. 1 receptors: a potential mechanism regulating stress adaptation. Am J Physiol 2001, 280:R935-R946.
21. 1 receptor phosphorylation and βarrestin2 recruitment: a mechanism regulating stress and anxiety responses. Am J Physiol 2007, 293:R209-R222.
22. Kohout T.A., Lin F.-T., Perry S.J., Conner D.A., Lefkowitz R.J. β-Arrestin 1 and 2 differentially regulate heptahelical receptor signaling and trafficking. Proc Natl Acad Sci USA 2001, 98:1601-1606.
23. Hsu S.Y., Hsueh A.J. Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nat Med 2001, 7:605-611.
24. Oakley R.H., Laporte S.A., Holt J.A., Barak L.S., Caron M.G. Molecular determinants underlying the formation of stable intracellular G protein-coupled-β-arrestin complexes after receptor endocytosis. J Biol Chem 2001, 276:19452-19460.
25. Oakley R.H., Cowan C.L., Hudson C.C., Loomis C.R. Transfluor provides a universal cell-based assay for screening G protein coupled receptors. Handbook of assay development in drug discovery 2006, 435-457. Marcel Dekker, New York. L. Minor (Ed.).
26. Oakley R.H., Hudson C.C., Cruickshank R.D., Meyers D.M., Payne R.E., Rehm S.M., Loomis C.R. The cellular distribution of fluorescently labeled arrestins provides a robust, sensitive, and universal assay for screening G protein-coupled receptors. Assay Drug Dev Technol 2002, 1:21-30.
27. Hauger R.L., Smith R.D., Braun S., Dautzenberg F.M., Catt K.J. Rapid agonist-induced phosphorylation of the human CRF receptor, type 1: a potential mechanism for homologous desensitization. Biochem Biophys Res Commun 2000, 268:572-576.
28. Clark R.B., Knoll B.J., Barber R. Partial agonists and G protein-coupled receptor desensitization. Trends Pharmacol Sci 1999, 20:279-286.
29. Lewis K., Li C., Perrin M.H., Blount A., Kunitake K., Donaldson C., Vaughan J., Reyes T.M., Gulyas J., Fischer W., Bilezikjian L., Rivier J., Sawchenko P.E., Vale W.W. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Natl Acad Sci USA 2001, 98:7570-7575.
30. Reyes T.M., Lewis K., Perrin M.H., Kunitake K.S., Vaughan J., Arias C.A., Hogenesch J.B., Gulyas J., Rivier J., Vale W.W., Sawchenko P.E. Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci USA 2001, 98:2843-2848.
31. 1 receptor desensitization. Biochem Biophys Res Commun 2002, 298:303-308.
32. Dautzenberg F.M., Hauger R.L. G protein receptor kinase 3- and protein kinase C-mediated desensitization of the PACAP receptor, type 1 in human Y-79 retinoblastoma cells. Neuropharmacology 2001, 40:394-407.
33. Alonso N., Fernandez N., Notcovich C., Monczor F., Simaan M., Baldi A., Gutkind S., Davio C., Shayo C. Cross-desensitization and cointernalization of H1 and H2 histamine receptors reveal new insights into histamine signal integration. Mol Pharmacol 2013, 83:1087-1098.
34. Rivier J., Gulyas J., Kunitake K., DiGruccio M., Cantle J.P., Perrin M.H., Donaldson C., Vaughan J., Million M., Gourceroi G., Adelson D.W., Rivier C., Tache Y., Vale W. Stressin-1A, a potent corticotrophin releasing factor receptor 1 (CRF1)-selective peptide agonist. J Med Chem 2007, 50:1668-1674.
35. Tezval H., Jahn O., Todorovic C., Sasse A., Eckart K., Spiess J. Cortagine, a specific agonist of corticotropin-releasing factor receptor subtype 1, is anxiogenic and antidepressive in the mouse model. Proc Natl Acad Sci USA 2004, 101:9468-9473.
36. Tobin A. Are we beta-ARKing up the wrong tree? Casein kinase 1 alpha provides an additional pathway for GPCR phosphorylation. Trends Pharmacol Sci 2002, 337-343.
37. Oakley R.H., Barak L.S., Caron M.G. Real time imaging of GPCR-mediated arrestin translocation as a strategy to evaluate receptor-protein interactions. G protein coupled receptor-protein interactions 2005, 53-80. John Wiley & Sons, Hoboken, NJ. S.R. George, B.F. O'Dowd (Eds.).
38. Milan-Lobo L., Gsandtner I., Gaubitzer E., Runzler D., Buchmayer F., Kohler G., Bonci A., Freissmuth M., Sitte H.H. Subtype-specific differences in corticotropin-releasing factor receptor complexes detected by fluorescence spectroscopy. Mol Pharmacol 2009, 76:1196-1210.
39. Krasel C., Vilardaga J.P., Bunemann M., Lohse M.J. Kinetics of G-protein-coupled receptor signaling and desensitization. Biochem Soc Trans 2004, 32:1029-1031.
40. 2-adrenergic receptor. Biochemistry 2005, 44:6133-6143.
41. Reiner S., Ambrosio M., Hoffmann C., Lohse M.J. Differential signaling of the endogenous agonist at the beta2-adrenergic receptor. J Biol Chem 2010, 285:36188-36198.
42. Holmes K.D., Babwah A.V., Dale L.B., Poulter M.O., Ferguson S.S. Differential regulation of corticotropin releasing factor 1alpha receptor endocytosis and trafficking by beta-arrestins and Rab GTPases. J Neurochem 2006, 96:934-949.
43. Marion S., Oakley R.H., Kim K.M., Caron M.G., Barak L.S. A beta-arrestin binding determinant common to the second-intracellular loops of Rhodopsin-family G protein-coupled receptors. J Biol Chem 2006, 281:2932-2938.
44. Kelly E., Bailey C.P., Henderson G. Agonist-selective mechanisms of GPCR desensitization. Br Pharmacol 2008, 153(Suppl. 1):S379-S388.
45. Whalen E.J., Rajagopal S., Lefkowitz R.J. Therapeutic potential of β-arrestin- and G protein-biased agonists. Trends Mol Med 2011, 17:126-139.
46. Brar B.K., Chen A., Perrin M.H., Vale W. Specificity and regulation of extracellularly regulated kinase-1/2 phosphorylation through corticotropin-releasing factor (CRF) receptors 1 and 2b by the CRF/urocortin family of peptides. Endocrinology 2004, 145:1718-1729.
47. Van Pett K., Viau V., Bittencourt J.C., Chan R.K.W., Li H.-Y., Arias C., Prins G.S., Perrin M., Vale W., Sawchenko P.E. Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. J Comp Neurol 2000, 428:191-212.
48. Sananbenesi F., Fischer A., Schrick C., Spiess J., Radulovic J. Mitogen-activated protein kinase signaling in the hippocampus and its modulation by corticotropin-releasing factor receptor 2: a possible link between stress and fear memory. J Neurosci 2003, 23:11436-11443.
49. Ventura-Silva A.P., Pego J.M., Sousa J.C., Marques A.R., Rodrigues A.J., Marques F., Cerqueira J.J., Almeida O.F.X., Sousa N. Stress shifts the response of the bed nucleus of the stria terminalis to an anxiogenic mode. Eur J Neurosci 2013, 36:3396-3406.
50. Waselus M., Nazzaro C., Valentino R.J., Van Bockstaele E.J. Stress-induced redistribution of corticotropin-releasing factor receptor subtypes in the dorsal raphe nucleus. Biol Psychiatry 2009, 66:76-83.
51. Neufeld-Cohen A., Kelly P.A.T., Paul E.D., Carter R.N., Skinner E., Olverman H.J., Vaughan J.M., Issler O., Kuperman Y., Lowry C.A., Vale W.W., Seckl J.R., Chen A., Jamieson P.M. Chronic activation of corticotropin-releasing factor receptor type 2 receptors reveals a key role of 5-HT1A receptor responsiveness in mediating behavioral and serotonergic responses to stressful challenge. Biol Psychiatry 2012, 72:437-447.
52. Hauger R.L., Olivares-Reyes J.A., Braun S., Dautzenberg F.M., Oakley R.H. Molecular and cell signaling targets for PTSD pathophysiology and pharmacotherapy. Neuropharmacology 2012, 62:705-714.